Validation of the Eortc Qlq-Bil21 Questionnaire for Measuring Quality of Life in Patients With Cholangiocarcinoma and Cancer of the Gallbladder Publisher Pubmed



Kaupproberts SD^{1, 2} ; Yadegarfar G³ ; Friend E¹ ; Odonnell CM¹ ; Valle JW⁴ ; Byrne C⁵ ; Bahar I⁶ ; Finchjones M⁷ ; Gillmore R⁸ ; Johnson CD⁹ ; Pereira SP¹⁰ ; Wiggers JK¹¹ ; Pinto M¹² ; Alsarireh B¹³ Show All Authors
Source: British Journal of Cancer Published:2016

Abstract

Background: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice. Methods: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and responsiveness to change were analysed. Results: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach's α-coefficients >0.70 for all scales overall. Intraclass correlations exceeded 0.80 for all scales. Convergent validity >0.40 was demonstrated for all items within scales, and discriminant validity was confirmed with values <0.70 for all scales compared with each other. Scale scores changed in accordance with Karnofsky performance status and in response to clinical change. Conclusions: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder. © 2016 Cancer Research UK. All rights reserved.